Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. The LDL-apheresis atherosclerosis regression study (LAARS)

Journal of the American College of Cardiology

Volumn 28, Issue 7, 1997, Pages 1696-1704

  Aengevaeren, Wim R M ^a   Kroon, Abraham A ^a   Stalenhoef, Anton F H ^a   Uijen, Gerard J H ^a   Van Der Werf, Tjeerd ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN; SIMVASTATIN;

ADULT; AGED; APHERESIS; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HEART MUSCLE PERFUSION; HUMAN; HYPERCHOLESTEROLEMIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANGIOGRAPHY, DIGITAL SUBTRACTION; ANTICHOLESTEREMIC AGENTS; BLOOD COMPONENT REMOVAL; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; LOVASTATIN; MALE; MIDDLE AGED; SIMVASTATIN;

EID: 0030478362     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(96)00388-9     Document Type: Article

References (49)

1. 1. Mabuchi H, Koizumi J, Shimizu M, Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989;79:225-32.
2. 2. Tatami R, Inoue N, Itoh H, et al., for the LARS Investigators. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. Atherosclerosis 1992;95:1-13.
3. 3. Gordon BR, Kelsey SF, Bilheimer DW, et al., for the Liposorber Study Group. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Am J Cardiol 1992;70:1010-6.
4. 4. Gordon BR, Stein E, Jones, P, Illingworth DR. Indications for low-density lipoprotein apheresis. Am J Cardiol 1994;74:1109-12.
5. 5. Hombach V, Borberg H, Gadzkowski A, Oette K, Stoffel W. Regression der Koronarsklerose bei familiarer Hypercholesterinämie IIa durch spezifische LDL-Apherese. Dtsch Med Wochenschr 1986;11:1709-15.
6. 6. Yamamoto A. Regression of atherosclerosis in humans by lowering serum cholesterol. Atherosclerosis 1991;89:1-10.
7. 7. Kitabatake A, Sato H, Hori M, et al., for the Osaka LDL-Apheresis Multicenter Trial Group. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density-lipoprotein-apheresis: 1-year follow-up study. Clin Ther 1994; 16: 416-28.
8. 8. Schuff-Werner P, Gohlke H, Bartmann U, et al., and the HELP-Study Group, The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. Eur J Clin Invest 1994;24:724-32.
9. 9. Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated by plasma exchange. BMJ 1985;291:1671-3.
10. 10. Thompson GR, Maher WMG, Matthews S, et al. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995;345:811-6.
11. 11. Kroon AA, Aengevaeren WRM, van der Werf T, et al. The LDL-Apheresis Atherosclerosis Regression Study (LAARS): effect of agressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996;93:1826-35.
12. 12. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:383-9.
13. 13. Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
14. 14. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
15. 15. Jukema JW, Bruschke AVG, van Boven AJ, et al., on behalf of the REGRESS Study Group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the "Regression Growth Evaluation Statin Study" (REGRESS). Circulation 1995;91:2528-40.
16. 16. de Feyter PJ, Serruys PW, Davies MJ, Richardson P, Lubsen J, Oliver MF. Quantitative coronary angiography to measure progression and regression of coronary atherosclerosis: value, limitations, and implications for clinical trials. Circulation 1991;84:412-23.
17. 17. Gibson CM, Sandor T, Stone PH, Pasternak RC, Rosner B, Sacks FM. Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials. Am J Cardiol 1992;69:1286-90.
18. 18. Hong MK, Mintz GS, Popma JJ, et al. Limitations of angiography for analyzing coronary atherosclerosis progression or regression Ann Intern Med 1994;121:348-54.
19. 19. Topol EJ, Nissen SE. Our preoccupation with coronary luminology: the dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 1995;92:2333-42.
20. 20. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-91.
21. 21. Cox DA, Vita JA, Treasure CB, et al. Atherosclerosis impairs flow-mediated dilatation of coronary arteries in humans. Circulation 1989;80:458-65.
22. 22. Lüscher TF, Richard V, Tschudi M, Yang Z, Boulanger C. Endothelial control of vascular tone in large and small coronary arteries. J Am Coll Cardiol 1990;15:519-27.
23. 23. Sellke FW, Armstrong ML, Harrison DG. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation 1990;81:1586-93.
24. 24. Zeiher AM, Drexler H, Sauerbier B, Just H. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension: endothelium-mediated coronary flow modulation in humans. J Clin Invest 1993;92:652-62.
25. 25. Gilligan DM, Guetta V, Panza JA, García CE, Quyyumi AA, Cannon RO. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 1994;90:35-41.
26. 26. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
27. 27. Egashira K, Hirooka Y, Kai H, et al. Reduction of serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519-24.
28. 28. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
29. 29. Anderson TJ, Meredith IT, Yeung AG, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
30. 30. Benzuly KH, Padgett RC, Kaul S, Piegors DJ, Armstrong ML Heistad DD. Functional improvement precedes structural regression of atherosclerosis. Circulation 1994;89:1810-8.
31. 31. Werf T van der, Heethaar RM, Stegehuis H, Meijler FL. The concept of apparent cardiac arrest as a prerequisite for coronary digital subtraction angiography. J Am Coll Cardiol 1984;4:239-44.
32. 32. Pijls NHJ, Uijen GJH, Hoevelaken A, et al. Mean transit time for assessment of myocardial perfusion by videodensitometry. Circulation 1990;81:1331-40.
33. 33. Pijls NHJ, Uijen GJH, Pijnenburg T, et al. Reproducibility of the mean transit time for maximal myocardial flow assessment by videodensitometry. Intern J Cardiac Imaging 1991;6:101-8.
34. 34. Pijls NHJ, Aengevaeren WRM, Uijen GJH, et al. Concept of maximal flow ratio for immediate evaluation of percutaneous transluminal coronary angioplasty result by videodensitometry. Circulation 1991;83:854-65.
35. 35. Wells R. Syndromes of hyperviscosity. N Engl J Med 1970;283:183-6.
36. 36. Tait GW, Packard CJ, Shepherd J, Hutton I, Lorimer RA. Cholesterol reduction and regression of coronary atherosclerosis: the Coronary Atheroma Regression Study. In: Gordon BR, Gotto AM, editors. The Treatment of Severe Hypercholesterolemia: Can We Impact Disease Course? Princeton (NJ): Exerpta Medica, 1992:80-9.
37. 37. Tsurumi Y, Nagashima H, Ichikawa KI, Sumiyoshi T, Hosoda S. Influence of plasma lipoprotein(a) levels on coronary vasomotor response to acetylcholine. J Am Coll Cardiol 1995;26:1242-50.
38. 38. Berdeaux A, Ghaleh B, Dubois-Randé JL, et al. Role of vascular endothelium in exercise-induced dilation of large epicardial coronary arteries in conscious dogs. Circulation 1994;89:2799-808.
39. 39. Igarashi K, Horimoto M, Takenaka T, Inoue H, Miyata S. Acute cholesterol lowering with LDL-apheresis improves endothelial function of the epicardial coronary artery in patients with hypercholesterolemia [abstract]. J Am Coll Cardiol 1996;27:19A.
40. 40. Gould KL, Ornisch D, Kirkeeidie R, et al. Improved stenosis geometry by quantitative coronary arteriography after vigorous risk factor modification. Am J Cardiol 1992;69:845-53.
41. 41. Glagov S, Weisenberg E, Zarins DK, Stankunavicus R, Kolettis BA. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:1371-5.
42. 42. Stiel GM, Stiel LSG, Schofer J, Donath K, Mathey DDG. Impact of compensatory enlargement of atherosclerotic coronary arteries on angiographic assessment of coronary artery disease. Circulation 1989;80:1603-9.
43. 43. Schächinger V, Zeiher AM. Quantitative assessment of coronary vasoreactivity in humans in vivo: importance of baseline vasomotor tone in atherosclerosis. Circulation 1995;92:2087-94.
44. 44. Gould KL, Martucci JP, Goldberg DI, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: a potential noninvasive marker of healing coronary endothelium. Circulation 1994;89:1530-8.
45. 45. Badger RS, Brown BG, Gallery CA, Bolson EL, Dodge HT. Coronary artery dilation and hemodynamic responses after isosorbide dinitrate therapy in patients with coronary artery disease. Am J Cardiol 1985;56:390-5.
46. 46. Jost S, Rafflenbeul W, Reil GH, et al. Reproducible uniform coronary vasomotor tone with nitrocompounds: prerequisite of quantitative coronary angiographia trials. Cathet Cardiovasc Diagn 1990;20:168-73.
47. 47. Schuff-Werner P, Schutz E, Seyde WC, et al. Improved haemorrheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin-induced extracorporeal LDL precipitation. Eur J Clin Invest 1989;19:30-7.
48. 48. Rubba P, Iannuzzi A, Postiglione A, et al. Hemodynamic changes in the peripheral circulation after repeat low density lipoprotein apheresis in familial hypercholesterolemia. Circulation 1990;81:610-6.
49. 49. Knisel W, Di Nicuolo A, Pfohl M, et al. Different effects of two methods of low-density lipoprotein apheresis on the coagulation and fibrinolytic system. J Intern Med 1993;234:479-87.